Cigna (NYSE:CI) has entered into a first-of-its-kind contract with AstraZeneca (NYSE:AZN) to help ensure that customers are given an appropriate cholesterol-lowering medication based on their treatment needs. For Cigna customers who are at increased risk for atherosclerotic cardiovascular disease (ASCVD) and need to aggressively manage their low-density lipoprotein cholesterol (LDL-C), CRESTOR
(rosuvastatin calcium), a brand-name, cholesterol-lowering drug manufactured by AstraZeneca, can be prescribed and filled without requiring prior authorization.
As an integrated health services company, Cigna is able to use both medical and pharmacy information in predictive risk modeling to appropriately assess a customer’s overall health condition. This approach analyzes multiple clinical factors to identify customers most at risk for ASCVD related to high cholesterol. When a doctor prescribes CRESTOR, customers identified as being at higher risk will no longer be subject to “step therapy”–where a generic alternative is tried first–and can have their prescriptions for CRESTOR filled immediately.
“Our arrangement with Cigna is an evolutionary step in supporting patient health, and facilitating access to CRESTOR for high risk patients. Predictive risk modeling can be used to help support the right treatment for the right patient at the right time, and we are excited to be working with Cigna because they are the only insurance carrier or Pharmacy Benefit Manager we have seen who has offered this capability,” says Philip de Vane, MD, Executive Director of US Medical Affairs, AstraZeneca.
“Cigna's mission is to help the people we serve improve their health, well-being, and sense of security, and using predictive risk modeling for our customers aligns incentives to drive affordability and improved outcomes. It is a more effective way to manage prescription drug costs for employers and customers by making it easier for higher-risk patients to obtain important medicines like CRESTOR more quickly while still using generics where they are a viable alternative,” says Chris Hocevar, President of Cigna Pharmacy Management and Select Business. “It is exciting to break new ground with AstraZeneca because they share our commitment to patients.”